Tumor-bowel fistula as a rare form of recurrent ovarian cancer – imaging and treatment. The pilot study

Author:

Jankowska-Lombarska Melania1,Grabowska-Derlatka Laretta1,Derlatka Pawel1

Affiliation:

1. Medical University of Warsaw

Abstract

Abstract Background. The aim of this pilot study was to evaluate the value of imaging techniques (CT and MRI) in the diagnosis of a tumor-bowel fistula as a rare form of epithelial ovarian cancer (EOC) relapse. We also performed an initial assessment of the effectiveness of the treatment of this form of relapse. Methods. The study group consisted of 8 patients with suspected platinum-sensitive recurrence in the form of a tumor/bowel fistula. All patients finished their first line of chemotherapy and subsequently showed complete remission for 6 months or more. To qualify patients for further treatment, CT and MRI were performed, which suggested the presence of a fistula between the recurrent tumor and intestine. DESKTOP study criteria were used to qualify patients for secondary cytoreduction. Second-line chemotherapy was given after secondary debulking. Results. In all patients, fistulas formed between the tumor and large bowel. On CT, the fistulas were indirectly visible. In all cases, the fistula was visible on MR images, which showed hypointensity on the T2 and T1 postcontrast sequences but did not show restricted diffusion on the diffusion-weighted imaging (DWI) sequence. Patients who were qualified for the study underwent secondary debulking with bowel resection. In all eight cases, the fistula between the tumor and surrounding organs was confirmed. During surgery, seven intestinal anastomoses and one colostomy were performed. No residual macroscopic tumor remained in seven cases (resection R0-87,5%). The progression-free survival was 8.4-22.6 months (median 13.4). In the group with cytoreduction R0, the median PFS was 15.5 months (12-22). Conclusion. In the case of relapsed EOC in patients with clinical symptoms in the form of a fistula, CT should not be the only diagnostic method, as MRI is a superior method for diagnosing fistulas. Bowel resection with simultaneous anastomosis seems to be a good and safe solution for these patients. However, an appropriate qualification for surgery is essential.

Publisher

Research Square Platform LLC

Reference26 articles.

1. "Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: Esmo Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up;Ledermann JA;Ann Oncol,2013

2. Lowe, K. A., V. M. Chia, A. Taylor, C. O'Malley, M. Kelsh, M. Mohamed, F. S. Mowat, and B. Goff. "An International Assessment of Ovarian Cancer Incidence and Mortality." Gynecol Oncol 130, no. 1 (2013): 107–14.

3. Chi. "Optimal Primary Management of Bulky Stage Iiic Ovarian, Fallopian Tube and Peritoneal Carcinoma: Are the Only Options Complete Gross Resection at Primary Debulking Surgery or Neoadjuvant Chemotherapy?";Sioulas VD;Gynecol Oncol,2017

4. Research European Organization for, Group Treatment of Cancer-Gynaecological Cancer, and Ncic Clinical Trials Group. "Neoadjuvant Chemotherapy or Primary Surgery in Stage Iiic or Iv Ovarian Cancer.";Vergote I;N Engl J Med,2010

5. Perren, and Icon trial investigators. "Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (Icon7): Overall Survival Results of a Phase 3 Randomised Trial;Oza AM;Lancet Oncol,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3